Pfizer – Allergan Deal’s Cancellation Loses Investment Banks Millions

Pfizer and Allergan announced that they’re canceling their planned merger because of new tax limitations on inversion deals, and this is apparently hitting the investment banks that were handling the transaction to the tune of $350 million.